← Back to Search

Virus Vaccine

UB-612 for Coronavirus Vaccines

Phase 3
Waitlist Available
Research Sponsored by Vaxxinity, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 1, 15 and 29, and months 6 and 12
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial tests a new COVID-19 vaccine called UB-612 as a booster shot for people who were vaccinated with a different COVID-19 vaccine some time ago. The goal is to see if this booster can improve their immune response.

Eligible Conditions
  • Coronavirus Vaccines

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 1, 15 and 29, and months 6 and 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 1, 15 and 29, and months 6 and 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Boost in neutralizing antibody titers against Wuhan strain at Day 29
Presence of adverse events of special interest
Presence of medically attended adverse events
+3 more
Secondary study objectives
Boost in neutralizing antibody titers against Omicron strain at Day 29
Kinetics and duration of antibody response - AUC via binding to S1-RBD
Kinetics and duration of antibody response - AUC via neutralizing antibodies
+10 more
Other study objectives
Ability to boost cellular immunity
Ability to boost humoral immunity (neutralizing) against additional variant - GMFI via neutralizing antibodies
Ability to boost humoral immunity (neutralizing) against additional variant - GMR via neutralizing antibodies
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

8Treatment groups
Experimental Treatment
Active Control
Group I: open-label UB-612 boost of BNT162b2Experimental Treatment1 Intervention
A single injection of UB-612 on Day 1 in an open-label fashion in subjects who completed the primary immunization series with BNT162b2.
Group II: double-blind UB-612 boost of Sinopharm BIBPExperimental Treatment1 Intervention
A single injection of UB-612 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with Sinopharm BIBP.
Group III: double-blind UB-612 boost of ChAdOx1-SExperimental Treatment1 Intervention
A single injection of UB-612 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with ChAdOx1-S.
Group IV: double-blind UB-612 boost of BNT162b2Experimental Treatment1 Intervention
A single injection of UB-612 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with BNT162b2
Group V: open-label BNT162b2 boostActive Control1 Intervention
A single injection of BNT162b2 on Day 1 in an open-label fashion in subjects who completed the primary immunization series with BNT162b2.
Group VI: double-blind ChAdOx1-S boostActive Control1 Intervention
A single injection of ChAdOx1-S on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with ChAdOx1-S.
Group VII: double-blind BNT162b2 boostActive Control1 Intervention
A single injection of BNT162b2 on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with BNT162b2.
Group VIII: double-blind Sinopharm BIBPActive Control1 Intervention
A single injection of Sinopharm BIBP on Day 1 in a double-blinded fashion in subjects who completed the primary immunization series with Sinopharm BIBP.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
UB-612
2020
Completed Phase 1
~110

Find a Location

Who is running the clinical trial?

Vaxxinity, Inc.Lead Sponsor
7 Previous Clinical Trials
4,161 Total Patients Enrolled
Syneos HealthOTHER
175 Previous Clinical Trials
67,455 Total Patients Enrolled
Coalition for Epidemic Preparedness InnovationsOTHER
36 Previous Clinical Trials
75,007 Total Patients Enrolled
~263 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top